Drug Name: Spevigo
Active Ingredient: spesolimab-sbzo
Indications: To treat generalized pustular psoriasis flares
Approval Date: 9/1/2022
Company: Boehringer Ingelheim International GmbH
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf